Aarti Pharmalabs, a key player in generic APIs, Xanthine derivatives (boasting 15-20% global market share), and CDMO/CMO services, shows robust performance.

For FY25, international sales contributed 52%, balancing the domestic market.

The company is strategically expanding, evidenced by a new R&D center, enhanced Xanthine capacity to 5,000 TPA, and a significant greenfield project at Atali.

Key recent milestones include securing USFDA approval for its Dombivli unit and commissioning a 21 MW solar power project in Akola, boosting sustainability efforts.

For FY25 (Consolidated), Revenue grew 14.2% to 2,115.1 Cr.

Profit after Tax jumped 25.6% to 272.4 Cr, with Earnings Per Share (EPS) up 25.5%. EBITDA margin improved to 21.96%. The company maintains a healthy financial position with a Net Debt/Equity of 0.19x. Looking ahead, Phase 1 of the Atali greenfield site is expected to commission in 2025, adding over 450 kL of reactor capacity, signaling future growth.